Maphoshane Nchabeleng

Safety and efficacy of the HVTN 503/Phambili Study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled test-of-concept phase 2b study

Glenda Gray, Mary Allen, Zoe Moodie et al. · The Lancet Infectious Diseases · 2011 · 382 citations · Full text

Vaccination, Hvtn 503/Phambili, Human Retrovirus +9

Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120–MF59 in Adults

Glenda Gray, Linda‐Gail Bekker, Fatima Laher et al. · New England Journal of Medicine · 2021 · 221 citations · Full text

Outbreak of multidrug-resistant tuberculosis in South Africa undetected by WHO-endorsed commercial tests: an observational study

Ndivhuho Makhado, Edith Matabane, Mauro Faccin et al. · The Lancet Infectious Diseases · 2018 · 140 citations

Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, South Africa +10

Recombinant adenovirus type 5 HIV gag/pol/nef vaccine in South Africa: unblinded, long-term follow-up of the phase 2b HVTN 503/Phambili study

Glenda Gray, Zoe Moodie, Barbara Metch et al. · The Lancet Infectious Diseases · 2014 · 119 citations · Full text

Vaccination, Vaccine Development, Phase 2B +9

Antibiotic resistance of Streptococcus agalactiae isolated from pregnant women in Garankuwa, South Africa

John Y. Bolukaoto, Maropeng C. Monyama, Martina O. Chukwu et al. · BMC Research Notes · 2015 · 110 citations · Full text